<DOC>
	<DOCNO>NCT02792335</DOCNO>
	<brief_summary>To describe rate discontinuation among Non-Valvular Atrial Fibrillation ( NVAF ) patient warfarin switch Novel oral anticoagulant ( NOACs ) .</brief_summary>
	<brief_title>Oral Anticoagulant Discontinuation , Adherence Patterns , Hospitalizations Costs Non-Valvular Atrial Fibrillation ( NVAF ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Individuals NVAF warfarin switch NOACs ( dabigatran , rivaroxaban apixaban ) within study period January 01 , 2013 March 31 , 2014 Individuals â‰¥18 year old index date At least 1 year baseline period history continuous warfarin use baseline period least 3 month immediately index date At least 1 diagnosis AF 12 month prior index date Continuous eligibility medical pharmacy benefit least 12 month index date 1 month index date Individuals diagnosis valvular heart disease cardiac surgery 12 month prior index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>